BioCentury
ARTICLE | Finance

Solidifying Atreca’s repertoire

How Atreca parlayed preclinical cancer immunotherapy data into mega-round

September 14, 2018 11:48 PM UTC

Atreca Inc. parlayed preclinical proof-of-concept data from its antibody platform into a $125 million series C round, which will enable the cancer immunotherapy company to bring its two lead programs into the clinic.

An undisclosed, U.S.-based healthcare fund led the untranched round, which was announced on Sept. 12. Fellow existing investors Wellington Capital and Cormorant Asset Management as well as new investors Aisling Capital, EcoR1 Capital, Boxer Capital of the Tavistock Group, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management also participated...

BCIQ Company Profiles

Atreca Inc.